HIV-2 They have published the revised study (March 8) re the efficacy of Trogarzo for HIV2 and Christian is one of the co authors.
https://pubmed.ncbi.nlm.nih.gov/35262531/?utm_source=gquery
The original PR below:
“Based on results obtained in vitro, it is expected that ibalizumab could have some efficacy in patients infected with HIV-2. HIV-2 multidrug resistance is on the rise in Europe and West Africa and there are limited therapeutic options, if any. The results obtained by the team of researchers in Paris are good news to patients with HIV-2 as ibalizumab could become an add-on to an optimized background regimen for people with an uncontrolled HIV-2,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.
Theratechnologies Announces Ibalizumab Inhibits HIV-2 In